Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained
If you take very high amounts over a short amount of time, you could damage your kidneys or even die
Ensure your TRT provider coordinates care and reviews your compounded medication with your full medical record
While Ozempic and other GLP-1 receptor agonists can help patients lose weight, they work best in conjunction with healthy lifestyle changes
US$ 20.43
US$ 20.20
US$ 24.96
US$ 27.41
US$ 23.05
US$ 29.70
US$ 23.44
US$ 21.36
US$ 25.53
